Literature DB >> 7216464

Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections.

H J Zweerink, L W Stanton.   

Abstract

Radioimmunoprecipitation assays were used to identify antibodies against a number of herpes simplex virus type 1-specific antigens in serum samples from individuals with recurrent facial herpes virus infections and from seropositive individuals without recurrent infections. Individuals with recurrent infections contributed three sequential serum samples each: immediately after the appearance of lesions, 3 weeks later, and 3 months later. Antibodies against at least 18 viral polypeptides were present in all positive sera: these included antibodies against the major nucleocapsid polypeptide (approximate molecular weight, 150,000) and against two glycopolypeptides with molecular weights of 115,000 to 130,000. No significant differences were observed between the serum samples in regard to their virus-specific antibody composition. The high-molecular-weight glycopolypeptides were partially purified and used in quantitative titration experiments. All sera tested were equally reactive with this material. It was concluded that under the experimental conditions an individual's susceptibility to recurrent herpetic infections could not be correlated with quantitative or qualitative changes in the levels of virus-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7216464      PMCID: PMC351354          DOI: 10.1128/iai.31.2.624-630.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

Review 1.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

2.  Herpesviruses in renal transplant patients.

Authors:  F D Pien; T F Smith; C F Anderson; M L Webel; H F Taswell
Journal:  Transplantation       Date:  1973-11       Impact factor: 4.939

Review 3.  Infection with herpes-simplex viruses 1 and 2. 1.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

4.  Proteins specified by herpes simplex virus. XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

5.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

6.  Maintenance of latent herpetic infection: an apparent role for anti-viral IgG.

Authors:  J G Stevens; M L Cook
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

Review 7.  Infectious complications of neoplastic disease.

Authors:  D Armstrong; L S Young; R D Meyer; A H Blevins
Journal:  Med Clin North Am       Date:  1971-05       Impact factor: 5.456

8.  A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans.

Authors:  R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

9.  A useful quantitative semimicromethod for viral plaque assay.

Authors:  B Rager-Zisman; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1973-04

10.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01
View more
  16 in total

1.  Variation in lymphoproliferative responses during recrudescent orofacial herpes simplex virus infections.

Authors:  J P Vestey; M Norval; S Howie; J Maingay; W A Neill
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.

Authors:  J Kahlon; F D Lakeman; M Ackermann; R J Whitley
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

3.  Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission.

Authors:  Z Mikloska; A L Cunningham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains.

Authors:  Y M Centifanto-Fitzgerald; E D Varnell; H E Kaufman
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  Immunity against infection with Trypanosoma cruzi in mice correlates with presence of antibodies against three trypomastigote polypeptides.

Authors:  H J Zweerink; H D Weston; O F Andersen; S S Garber; E C Hayes
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

6.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.

Authors:  Z Mikloska; P P Sanna; A L Cunningham
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

8.  Virus-specific antibodies in sera from patients with genital herpes simplex virus infection.

Authors:  H J Zweerink; L Corey
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

9.  Herpes simplex virus and intraoral ulcers in immunocompromised patients with haematologic malignancies.

Authors:  O J Bergmann; S C Mogensen; J Ellegaard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

10.  Herpes simplex virus-specific serum immunoglobulin a: detection in patients with primary or recurrent herpes infections and in healthy adults.

Authors:  M G Friedman; N Kimmel
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.